Back to search

National and Kapodistrian University of Athens

Ανάπτυξη και αξιολόγηση αντισωμάτων για τη μελέτη μικρομοριακών ενώσεων με βιοχημικό ενδιαφέρον

Abstract

dc:description

In the present work, polyclonal antibodies for biotin, a low molecular weight substance (hapten) of biochemical and biotechnological interest were developed and evaluated. Anti-biotin antibodies are generally considered important bioanalytical tools, since they can be used in research on biotin and endogenous biotinylated proteins, while they may also serve as alternative reagents in various biotechnological systems (e.g. for purifying, immobilizing or “labeling” biomolecules) that employ special biotinylated probes in combination with biotin-binding proteins (e.g. avidin, streptavidin). From a different point of view, anti-biotin antibodies can be considered “model” anti-hapten antibodies, since their functional binding characteristics for the corresponding hapten (biotin) can be easy and reliably evaluated by using avidin or streptavidin as control binding biomolecules. The antibodies for biotin were developed against the synthetic derivative biotin-aminocaproic acid-lysine (BAL), which was conjugated to bovine thyroglobulin via glutaraldehyde and then used for immunizing New Zealand white rabbits. BAL was synthesized on a commercially available resin following the Fmoc-solid phase strategy, which is widely applied to the field of peptide synthesis. This approach has greatly facilitated the experimental procedure, decreased the undesirable side-reactions (due to the presence of special protecting groups in each of the “building moieties” of BAL), overcame the necessity for intermediate purification steps and led to a final product of high purity and yield. The aminocaproic acid-lysine “long bridge” was used in order to keep the hapten far apart from the carrier protein, thus “projecting” it to the immunological system of the host animal. Lysine was selected due to its Nε-amino group, through which BAL can be conjugated -via glutaraldehyde- to the carrier protein molecule. The anti-BAL antibodies were evaluated in an ELISA system, which was developed in-house. A biotin / polylysine-dendrimer conjugate was used for immobilizing biotin on the ELISA microwells. The polylysine-dendrimer was synthesized -for the first time, as a part of the experimental work of this Thesis- following the Fmoc-solid phase strategy and using Fmoc-Lys(Nε-Fmoc)-OH and Fmoc-Lys(Nε-Boc)-OH as building blocks. The titer of the anti-BAL antibodies was ~ 1:50,000. Displacement curves were obtained in the presence of increasing concentrations of not only BAL and BA but also free biotin (10 ng/mL - 10 μg/mL). In the frames of the Thesis, an ELISA-type, enzyme-binding assay was also developed, in which the biotin / polylysine-dendrimer conjugate and streptavidin-HRP were used. In this assay, a displacement curve was obtained in the presence of very low biotin concentrations (100 - 800 pg/mL). The displacement curves of the ELISA and the ELISA-type, enzyme-binding assay were applied to the determination of biotin in serial dilutions of a commercially available pharmaceutical preparation containing biotin. The anti-BAL antibodies were applied, in parallel with streptavidin, to preliminary immunocytology experiments with HeLa cells, which led to a clear immunostaining of the cell cytoplasm, while the cell nucleus was not stained. The anti-BAL antibodies were also applied, in parallel with streptavidin, to the western-blot analysis of HeLa and MDA-MB-231 cell lysates, leading to a similar pattern with that of streptavidin. By following a similar approach with the above described one, New Zealand white rabbits were immunized against the synthetic derivative carnitine-aminocaproic acid-lysine (CAL), aiming at the development of antibodies for the natural hapten carnitine, due to its biological importance as well as to the lack of any commercially available antibodies for it. In this case, however, the antibodies developed recognized the synthetic derivative CAL but not free carnitine. Antibodies specific for carnitine were not developed when other carnitine derivatives were used for immunization, either. This finding along with the above mentioned lack of commercially available anti-carnitine antibodies as well as of any (but just one) relevant articles in the literature led us to speculate that these negative results may be attributed to low intrinsic antigenicity of carnitine rather than to the design of CAL. Overall, we strongly believe that the possibility of using synthetic derivatives of the general type “hapten-aminocaproic acid-lysine” in order to develop efficient and specific antibodies for carboxyl-bearing haptens should be further investigated.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2009

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Papasarantos, Ilias
  • Παπασαράντος, Ηλίας

Subjects

dc:subject × 20

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/23402

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Papasarantos, Ilias; Παπασαράντος, Ηλίας. Ανάπτυξη και αξιολόγηση αντισωμάτων για τη μελέτη μικρομοριακών ενώσεων με βιοχημικό ενδιαφέρον. National and Kapodistrian University of Athens, 2009. http://hdl.handle.net/10442/hedi/23402